Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40BBS | ISIN: US2498454055 | Ticker-Symbol:
NASDAQ
04.06.25 | 18:22
0,713 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DERMATA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DERMATA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DERMATA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.05.Dermata Therapeutics, Inc. - 8-K, Current Report1
14.05.Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results222- Dermata announced positive topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints -- Dermata entered into a Clinical...
► Artikel lesen
14.05.Dermata Therapeutics, Inc. - 8-K, Current Report5
14.05.Dermata Therapeutics, Inc. - 10-Q, Quarterly Report2
15.04.Dermata Therapeutics files to sell 10.01M shares of common stock for holders1
DERMATA THERAPEUTICS Aktie jetzt für 0€ handeln
15.04.Dermata meldet frühen Erfolg bei Aknebehandlung mit XYNGARI3
15.04.Dermata reports early success in acne treatment with XYNGARI2
15.04.Dermata Therapeutics: Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks251- Dermata previously announced XYNGARI produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -- Additional data analysis revealed that XYNGARI...
► Artikel lesen
15.04.Dermata Therapeutics, Inc. - 8-K, Current Report2
28.03.Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules442SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of...
► Artikel lesen
27.03.Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne2
27.03.Dermata Therapeutics, Inc.: BREAKING: Dermata's XYNGARI Phase 3 Trial Topline Data Meets All Primary Endpoints187- XYNGARI achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI is the first once-weekly...
► Artikel lesen
27.03.Dermata shares rise on positive acne treatment trial results1
25.03.Dermata Therapeutics, Inc. - 8-K, Current Report3
17.03.Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results302- Dermata expects to announce topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -- The Company recently entered into a Clinical...
► Artikel lesen
17.03.Dermata Therapeutics, Inc. - 8-K, Current Report2
17.03.Dermata Therapeutics, Inc. - 10-K, Annual Report4
04.03.Dermata Therapeutics, Inc.: Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI Phase 3 STAR-1 Clinical Trial for Acne128- STAR-1 topline results expected by the end of March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year - - XYNGARI Phase 3 STAR-1 trial...
► Artikel lesen
25.02.Dermata Therapeutics: Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis590- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company recently entered into a Clinical Trial...
► Artikel lesen
29.01.Dermata Therapeutics: Dermata to Present on BioPub on January 31, 2025281- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community -SAN DIEGO, CA / ACCESS Newswire / January...
► Artikel lesen
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1